UPB
NASDAQ · Biotechnology
Upstream Bio Inc
$6.25
+0.10 (+1.63%)
Open$6.26
Previous Close$6.15
Day High$6.52
Day Low$6.15
52W High$33.68
52W Low$5.85
Volume—
Avg Volume754.4K
Market Cap340.12M
P/E Ratio—
EPS$-2.90
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+294.9% upside
Current
$6.25
$6.25
Target
$24.68
$24.68
$18.50
$24.68 avg
$35.72
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.96M | 2.22M | 177.59M |
| Net Income | -148,517,489 | -100,470,339 | -3,219,143 |
| Profit Margin | -5,026.0% | -4,774.7% | -1.8% |
| EBITDA | -165,841,555 | -118,422,637 | -5,179,349 |
| Free Cash Flow | — | — | -3,332,995 |
| Rev Growth | +33.0% | +33.0% | -5.8% |
| Debt/Equity | — | — | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |